0.3521

35.31% -0.1931

Bioline Rx Ltd Adr (BLRX)

Overview News Price History Option Chain Why BLRX Down? Discussions Forecast Stock Split

Bioline Rx Ltd Adr stock is traded at $0.3521, with a volume of 6.02M. It is down -35.31% in the last 24 hours and down -25.12% over the past month. BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Previous Close:

$0.5452

Open:

$0.4344

24h Volume:

6.02M

Relative Volume:

15.18

Market Cap:

$42.88M

Revenue:

Net Income/Loss:

$-60.61M

P/E Ratio:

-0.5868

EPS:

-0.6

Net Cash Flow:

$-22.91M

1W Performance:

-22.99%

1M Performance:

-25.12%

6M Performance:

-43.38%

1Y Performance:

-76.80%

1-Day Range:

$0.35

$0.4344

1-Week Range:

$0.35

$0.565

52-Week Range:

$0.35

$1.89

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name

Bioline Rx Ltd Adr

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

Address

Employee

Twitter

Next Earnings Date

2024-12-21

Latest SEC Filings

BLRX's Discussions on Twitter

Compare BLRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BLRX	0.352	42.88M	0	-60.61M	-22.91M	-0.60
VRTX	448.04	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	746.99	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.26	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.69	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.80	24.49B	3.30B	-501.07M	1.03B	11.54

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-18-17	Upgrade	Maxim Group	Hold → Buy
Feb-13-17	Initiated	Rodman & Renshaw	Buy
Aug-12-16	Downgrade	Maxim Group	Buy → Hold
Aug-17-15	Reiterated	Maxim Group	Buy
Jul-27-15	Reiterated	ROTH Capital	Buy
Jun-22-15	Initiated	JMP Securities	Mkt Outperform

View All

Bioline Rx Ltd Adr Stock (BLRX) Latest News

09:52 AM

BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com

09:52 AM

07:38 AM

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - TipRanks

07:38 AM

07:21 AM

BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India

Oct 24, 2024

Oct 16, 2024

BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks

Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide - Investing.com

Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK

Oct 16, 2024

Oct 15, 2024

BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com

Oct 15, 2024

Oct 07, 2024

Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle

Oct 07, 2024

Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex

Oct 07, 2024

Oct 02, 2024

BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com

Oct 02, 2024

Oct 01, 2024

BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks

Oct 01, 2024